Plain-English translation of NCT07281014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Researchers want to understand how well spironolactone, a medication commonly used to treat heart failure, actually works in the body. They will give participants the medication in different combinations with IV infusions to measure how it affects salt and potassium levels in the urine and blood.
Spironolactone is recommended for heart failure patients, but doctors aren't completely sure how well it works at the doses typically prescribed. This study will help clarify whether the standard dose is effective enough or if adjustments might be needed in the future.
You likely qualify if…
You likely don't qualify if…
You will visit the research center four times over 8 weeks, with each visit about 2 weeks apart. At each visit, you will receive an IV infusion and take a pill (some will be placebo), then have blood and urine tests to measure salt and potassium levels. The study is "blinded," meaning you won't know which treatment you're receiving, and researchers will make sure there's time between visits for your body to fully clear the medication before the next round.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
Yale University
Collaborators
Boehringer Ingelheim
Enrollment target
~20 participants
Started
January 2026
Primary completion
August 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Veena Rao
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.